$SBFM
Sunshine Biopharma Inc.

2022 Q3 Form 10-Q Financial Statement

#000168316822005298 Filed on August 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $132.8K $150.3K $122.7K
YoY Change 163.61% 184.27% 206.17%
Cost Of Revenue $65.78K $74.68K $59.85K
YoY Change 237.18% 303.36% 223.16%
Gross Profit $67.03K $75.62K $62.80K
YoY Change 117.12% 120.1% 191.55%
Gross Profit Margin 50.47% 50.31% 51.2%
Selling, General & Admin $1.422M $723.2K $921.4K
YoY Change 371.58% 217.17% -18.26%
% of Gross Profit 2121.18% 956.3% 1467.2%
Research & Development $362.5K $45.94K $361.7K
YoY Change 62.94% -76.04% 116.83%
% of Gross Profit 540.84% 60.75% 575.88%
Depreciation & Amortization $789.00 $2.287K $3.110K
YoY Change -75.27% -28.35% -2.2%
% of Gross Profit 1.18% 3.02% 4.95%
Operating Expenses $362.5K $45.94K $1.286M
YoY Change -31.23% -76.04% -0.85%
Operating Profit -$1.718M -$695.8K -$1.223M
YoY Change 246.19% 79.05% -4.1%
Interest Expense $2.00 $0.00 -$12.87K
YoY Change -100.0% -100.0% -74.12%
% of Operating Profit
Other Income/Expense, Net $261.0K $156.9K -$12.87K
YoY Change -106.3%
Pretax Income -$1.457M -$538.9K -$1.236M
YoY Change -63.93% -81.28% -80.01%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.457M -$538.9K -$1.236M
YoY Change -63.93% -81.28% -80.01%
Net Earnings / Revenue -1097.09% -358.51% -1007.93%
Basic Earnings Per Share -$0.08 -$0.03
Diluted Earnings Per Share -$77.15K -$34.00K -$234.5K
COMMON SHARES
Basic Shares Outstanding 18.89M shares 15.85M shares
Diluted Shares Outstanding 18.89M shares 15.85M shares 5.273M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.56M $41.73M $13.18M
YoY Change 1599.31% 2304.93% 633.48%
Cash & Equivalents $40.56M $41.73M $13.18M
Short-Term Investments
Other Short-Term Assets $34.98K $56.15K $46.22K
YoY Change 7.17% 141.19% 148.76%
Inventory $269.6K $205.4K $181.5K
Prepaid Expenses $27.39K $48.56K
Receivables $22.00 $24.00 $20.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $40.86M $41.99M $13.41M
YoY Change 1539.88% 2228.1% 627.82%
LONG-TERM ASSETS
Property, Plant & Equipment $3.770K $1.642K $3.980K
YoY Change -63.15% -87.82% -76.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.770K $1.642K $3.970K
YoY Change -63.18% -87.82% -76.13%
TOTAL ASSETS
Total Short-Term Assets $40.86M $41.99M $13.41M
Total Long-Term Assets $3.770K $1.642K $3.970K
Total Assets $40.86M $41.99M $13.41M
YoY Change 1533.32% 2210.92% 621.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $480.2K $104.7K $95.23K
YoY Change 747.08% 1.45% -35.9%
Accrued Expenses $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $480.2K $104.7K $95.23K
YoY Change 1.82% -83.53% -88.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $480.2K $104.7K $95.23K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $480.2K $104.7K $95.23K
YoY Change -86.94% -96.11% -96.76%
SHAREHOLDERS EQUITY
Retained Earnings -$35.89M -$34.43M
YoY Change
Common Stock $18.89K $18.89K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $40.38M $41.89M $13.31M
YoY Change
Total Liabilities & Shareholders Equity $40.86M $41.99M $13.41M
YoY Change 1533.32% 2210.92% 621.53%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.457M -$538.9K -$1.236M
YoY Change -63.93% -81.28% -80.01%
Depreciation, Depletion And Amortization $789.00 $2.287K $3.110K
YoY Change -75.27% -28.35% -2.2%
Cash From Operating Activities -$1.124M -$573.8K -$1.304M
YoY Change 87.04% -7.28% 338.6%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 29.12M 12.44M
YoY Change -100.0% 5188.97% 1028.65%
NET CHANGE
Cash From Operating Activities -1.124M -573.8K -1.304M
Cash From Investing Activities $0.00
Cash From Financing Activities 0.000 29.12M 12.44M
Net Change In Cash -1.124M 28.55M 11.13M
YoY Change -266.51% -41962.01% 1283.66%
FREE CASH FLOW
Cash From Operating Activities -$1.124M -$573.8K -$1.304M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Inventory Net
InventoryNet
205371 usd
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
1900000 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18885632 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18885632 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001402328
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41282
dei Entity Registrant Name
EntityRegistrantName
SUNSHINE BIOPHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
CO
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5566275
dei Entity Address Address Line1
EntityAddressAddressLine1
6500 Trans-Canada Highway
dei Entity Address Address Line2
EntityAddressAddressLine2
4th Floor
dei Entity Address Address Line3
EntityAddressAddressLine3
Pointe-Claire
dei Entity Address City Or Town
EntityAddressCityOrTown
Quebec
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H9R 0A5
dei City Area Code
CityAreaCode
(514)
dei Local Phone Number
LocalPhoneNumber
426-6161
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2021Q4 us-gaap Inventory Net
InventoryNet
105650 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
48562 usd
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2591240 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2591240 shares
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
0 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
29625 usd
CY2022Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
7590 usd
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
7590 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
41989322 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
2195830 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
69202 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
18886 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2591 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
64106 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1642 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7061 usd
CY2022Q2 us-gaap Assets
Assets
41990964 usd
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18885632 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41727775 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2045167 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7798 usd
CY2021Q4 us-gaap Assets
Assets
2202891 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
104684 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
42942 usd
CY2022Q2 us-gaap Interest Payable Current
InterestPayableCurrent
0 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
48287 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
104684 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
91229 usd
CY2021Q2 SBFM Consulting Expense
ConsultingExpense
21677 usd
CY2022Q2 us-gaap Liabilities
Liabilities
104684 usd
CY2021Q4 us-gaap Liabilities
Liabilities
1991229 usd
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
1000 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
100000 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
76331451 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32787384 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-34777 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-23139 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34430280 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32655174 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
41886280 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
211662 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41990964 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2202891 usd
CY2022Q2 us-gaap Revenues
Revenues
150307 usd
CY2021Q2 us-gaap Revenues
Revenues
52874 usd
us-gaap Revenues
Revenues
272952 usd
us-gaap Revenues
Revenues
92932 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
74683 usd
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
18515 usd
us-gaap Cost Of Revenue
CostOfRevenue
134528 usd
us-gaap Cost Of Revenue
CostOfRevenue
37035 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
75624 usd
CY2021Q2 us-gaap Gross Profit
GrossProfit
34359 usd
us-gaap Gross Profit
GrossProfit
138424 usd
us-gaap Gross Profit
GrossProfit
55897 usd
CY2022Q2 us-gaap Professional Fees
ProfessionalFees
41060 usd
CY2021Q2 us-gaap Professional Fees
ProfessionalFees
19800 usd
us-gaap Professional Fees
ProfessionalFees
114860 usd
us-gaap Professional Fees
ProfessionalFees
61200 usd
CY2022Q2 us-gaap Advertising Expense
AdvertisingExpense
87680 usd
CY2021Q2 us-gaap Advertising Expense
AdvertisingExpense
0 usd
us-gaap Advertising Expense
AdvertisingExpense
182720 usd
us-gaap Advertising Expense
AdvertisingExpense
0 usd
SBFM Consulting Expense
ConsultingExpense
107181 usd
SBFM Consulting Expense
ConsultingExpense
32570 usd
CY2022Q2 SBFM Officer And Director Remuneration
OfficerAndDirectorRemuneration
290000 usd
CY2022Q2 SBFM Patenting Fees
PatentingFees
3230 usd
CY2021Q2 SBFM Patenting Fees
PatentingFees
8377 usd
CY2022Q2 us-gaap Legal Fees
LegalFees
109130 usd
SBFM Patenting Fees
PatentingFees
11564 usd
SBFM Patenting Fees
PatentingFees
14570 usd
CY2021Q2 us-gaap Legal Fees
LegalFees
95034 usd
us-gaap Legal Fees
LegalFees
245355 usd
SBFM Office Expense
OfficeExpense
372912 usd
SBFM Office Expense
OfficeExpense
100803 usd
CY2022Q2 SBFM Consulting Expense
ConsultingExpense
101683 usd
us-gaap Legal Fees
LegalFees
102151 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45943 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
191760 usd
CY2022Q2 SBFM Office Expense
OfficeExpense
90407 usd
CY2021Q2 SBFM Office Expense
OfficeExpense
61117 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
407595 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
358546 usd
CY2022Q2 us-gaap Depreciation
Depreciation
2287 usd
CY2021Q2 us-gaap Depreciation
Depreciation
3192 usd
CY2021Q2 SBFM Officer And Director Remuneration
OfficerAndDirectorRemuneration
22000 usd
SBFM Officer And Director Remuneration
OfficerAndDirectorRemuneration
610000 usd
SBFM Officer And Director Remuneration
OfficerAndDirectorRemuneration
1043927 usd
us-gaap Depreciation
Depreciation
5397 usd
us-gaap Depreciation
Depreciation
6374 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
771420 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
422957 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2057584 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1720141 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-695796 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-388598 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1919160 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1664244 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
29 usd
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
8 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
20 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-6 usd
CY2022Q2 us-gaap Interest Income Debt Securities Operating
InterestIncomeDebtSecuritiesOperating
146043 usd
CY2021Q2 us-gaap Interest Income Debt Securities Operating
InterestIncomeDebtSecuritiesOperating
2 usd
us-gaap Interest Income Debt Securities Operating
InterestIncomeDebtSecuritiesOperating
146046 usd
us-gaap Interest Income Debt Securities Operating
InterestIncomeDebtSecuritiesOperating
2 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
-0 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
195630 usd
us-gaap Interest Expense
InterestExpense
12864 usd
us-gaap Interest Expense
InterestExpense
245341 usd
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
10852 usd
CY2021Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
221 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
10852 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
51252 usd
CY2022Q2 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
-0 usd
CY2021Q2 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
2295057 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
-0 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
7205843 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
156924 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2490456 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
144054 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7399936 usd
us-gaap Profit Loss
ProfitLoss
-1775106 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-538872 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-2879054 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9072945 usd
us-gaap Profit Loss
ProfitLoss
-9064180 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-538872 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2879054 usd
us-gaap Net Income Loss
NetIncomeLoss
-1775106 usd
us-gaap Net Income Loss
NetIncomeLoss
-9064180 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-12645 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-6702 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-11638 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-8765 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-551517 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2885756 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1786744 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.96
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15849518 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2392602 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9691265 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2293836 shares
us-gaap Profit Loss
ProfitLoss
-1775106 usd
us-gaap Profit Loss
ProfitLoss
-9064180 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5397 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6374 usd
us-gaap Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax
UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
20 usd
us-gaap Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax
UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
6 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
918000 usd
SBFM Stock Issued For Payment Interest On Notes Payable
StockIssuedForPaymentInterestOnNotesPayable
0 usd
SBFM Stock Issued For Payment Interest On Notes Payable
StockIssuedForPaymentInterestOnNotesPayable
38422 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
7205843 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
10852 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
51252 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7774 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1916 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
99721 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
27736 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
18937 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
12907 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
61742 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
35524 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
33795 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8765 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-48287 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1878010 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-916207 usd
SBFM Proceeds Public Offering Net
ProceedsPublicOfferingNet
-43560363 usd
SBFM Proceeds Public Offering Net
ProceedsPublicOfferingNet
-1918500 usd
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
-99000 usd
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
61500 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1900000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
327352 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41561363 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1652648 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2045167 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
989888 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
39683353 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
736441 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-12383 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11638 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41727775 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1735094 usd
SBFM Stock Issued For Note Conversions Including Interest
StockIssuedForNoteConversionsIncludingInterest
0 usd
SBFM Stock Issued For Note Conversions Including Interest
StockIssuedForNoteConversionsIncludingInterest
8237072 usd
us-gaap Interest Paid Net
InterestPaidNet
61151 usd
us-gaap Interest Paid Net
InterestPaidNet
142152 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
13314108 usd
CY2022Q2 SBFM Common Stock And Prefunded Warrants Issued In Underwritten Public Offering Net Of Issuance Costs
CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts
16752915 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
12370774 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-551517 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
41886280 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
211662 usd
SBFM Common Stock And Prefunded Warrants Issued In Underwritten Public Offering Net Of Issuance Costs
CommonStockAndPrefundedWarrantsIssuedInUnderwrittenPublicOfferingNetOfIssuanceCosts
30367185 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
13193177 usd
SBFM Preferred Stock Purchased From Related Party Value
PreferredStockPurchasedFromRelatedPartyValue
99000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1786744 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
41886280 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-1084389 usd
CY2021Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
3097435 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2885756 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-872710 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-954837 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
8237072 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
918000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9072945 usd
CY2022Q1 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
990000 shares
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-872710 usd
CY2022Q2 us-gaap Notes Payable
NotesPayable
0 usd
CY2021Q4 us-gaap Notes Payable
NotesPayable
1900000 usd
CY2022Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
0 usd
CY2021Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
48287 usd
CY2022Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
6833071 usd
us-gaap Dividends
Dividends
0 usd
CY2022Q2 us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
240000 usd
CY2021Q2 us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
25000 usd
us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
510000 usd
us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
125927 usd
CY2022Q2 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
50000 usd
us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
50000 usd
us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
0 usd
CY2021Q2 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
0 usd

Files In Submission

Name View Source Status
0001683168-22-005298-index-headers.html Edgar Link pending
0001683168-22-005298-index.html Edgar Link pending
0001683168-22-005298.txt Edgar Link pending
0001683168-22-005298-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_001.gif Edgar Link pending
image_001.jpg Edgar Link pending
image_002.gif Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sbfm-20220630.xsd Edgar Link pending
sbfm-20220630_cal.xml Edgar Link unprocessable
sbfm-20220630_def.xml Edgar Link unprocessable
sbfm-20220630_lab.xml Edgar Link unprocessable
sbfm-20220630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending
sunshinebio_ex3101.htm Edgar Link pending
sunshinebio_ex3102.htm Edgar Link pending
sunshinebio_ex3201.htm Edgar Link pending
sunshinebio_i10q-063022.htm Edgar Link pending
sunshinebio_i10q-063022_htm.xml Edgar Link completed